Abstract
Carbapenemase-producing
Klebsiella pneumoniae
infections carry serious clinical and infection-control implications. Isolates possessing such hydrolyzing enzymes have been described in the United States and around the world. Besides being resistant to carbapenems, they usually confer resistance to fluoroquinolones, piperacillin-tazobactam, and extended-spectrum cephalosporins. Tigecycline demonstrates in vitro activity against these organisms, but reported resistance raises concern about tigecycline use for these infections. We describe a carbapenemase-producing
K pneumoniae
evolving resistance to tigecycline in a 75-year-old male after a prolonged stay in a critical care unit.